Frees et al. reported that CaSR antagonist NPS 2143 was able to reverse Ca2+-induced increase in cell adhesion, migration and proliferation in renal carcinoma cells transfected with the CaSR plasmid [73]. Here, CASR is linked to renal carcinoma.